Close
To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.
CL1-95031-006A Phase 1/2, Safety Lead-in and Dose Expansion, Open-label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Activity of Ivosidenib in Combination with Nivolumab and Ipilimumab in Previously Treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation | |
|---|---|
| Local Project Reference: | 155357 |
| Principal Investigator | Prof John Bridgewater |
| Drug Class/ Treatment: | Ivosidenib (IDH1 Inhibitor) + Nivolumab + Ipilimumab Combination Therapy |
| Patient Population: | Nonresectable or Metastatic Cholangiocarcinoma with IDH1 Mutation |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
NuTide302A Phase Ib open label Study to assess NUC-3373 in patients with colorectal cancer: A Phase Ib open label study to assess the safety and pharmacokinetics of NUC-3373, a nucleotide analogue, given in combination with standard agents used in colorectal cancer treatment | |
|---|---|
| Local Project Reference: | 108215 |
| Principal Investigator | Dr. Khurum Khan |
| Drug Class/ Treatment: | NUC-3373 (Nucleotide Analogue) Part 3: Arm 3A - Combination with LV Q1W + Oxaliplatin + Bevacizumab |
| Patient Population: | Colorectal Cancer |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
